Cereno Scientific

Based in Sweden, Cereno Scientific is focused on the development of innovative, effective and safe treatments for people with rare cardiovascular and pulmonary diseases. Lead asset CS1, an HDAC inhibitor that acts as an epigenetic modulator, is currently being investigated in a Phase II clinical trial for the treatment of PAH.

Equities

Equities by Sector

Sectors

Megatrends

Thematics

Latest

Edison explains: Europe’s ageing buildings

Stock of the month – PZ Cussons

Q226 reflections: Leadership swings back – the value case holds

Audiovisual

Latest

The Metals Company – equity proposition

Vantage: Rockwood Strategic – UK small-cap value and active engagement

Bull, Bear & Beyond – Living REIT: executive interview

About Edison

Corporates

Investors

Careers

Cereno Scientific (OMX: CRNO-B)

Latest News

Latest Insights

Cereno Scientific — A step closer to Phase IIb for CS014

Cereno Scientific — Strategic financing strengthens partnering position

Bull, Bear & Beyond – Cereno Scientific: executive interview

Cereno Scientific – executive interview

Market Data

Sector

Equity Analyst

Key Management

Share Price Chart

Cereno Scientific – The investment case: capital markets day highlights

Cereno Scientific – executive interview

Cereno Scientific — CMD reaffirms shifting focus to clinical delivery

Cereno Scientific — Entering a value inflection phase

Cereno Scientific — Runway clears for Phase IIb with FDA nod

Cereno Scientific — Armed and ready for Phase II

Cereno Scientific – executive interview

Cereno Scientific – executive interview

Cereno Scientific — Momentum building ahead of Phase II

Cereno Scientific — Phase II calling for CS014 after Phase I success

Cereno Scientific – executive interview

Cereno Scientific — Improved liquidity with latest debt financing

Cereno Scientific — Four-month EAP data support CS1 plans

Cereno Scientific — Firing on all cylinders

Cereno Scientific — CS1 takes another step towards Phase IIb

Cereno Scientific — CS014 completes Phase I, path clears for Phase II

Cereno Scientific — Poised for active year in CVD and rare diseases

Cereno Scientific — CS014 achieves another Phase I milestone

Cereno Scientific – executive interview

Cereno Scientific — A productive period with plenty more to come

Cereno Scientific — New SEK250m financing secures runway into 2026

Cereno Scientific — CMD highlights a ‘rare’ portfolio refocus

Cereno Scientific – executive interview

Cereno Scientific — CS1 shines in Phase IIa PAH trial

Cereno Scientific — CS1 granted OMPD, complementing FDA ODD

Cereno Scientific — Pressing clinical assets forward to key inflection

Cereno Scientific — CS1 Phase II results inbound; first dose of CS014

Cereno Scientific — CS014 (second asset) crosses into the clinic

Cereno Scientific — All eyes on Q3 readout after Q1 update

Cereno Scientific — CS014 (thrombosis) progresses towards the clinic

Cereno Scientific – Executive interview with CSO and CMO

Cereno Scientific – executive interview

Cereno Scientific — Differentiated approach in CVD with potential